Medicines management programme: preferred medicines angiotensin-converting enzyme inhibitors

Hdl Handle:
http://hdl.handle.net/10147/325028
Title:
Medicines management programme: preferred medicines angiotensin-converting enzyme inhibitors
Authors:
Barry, Michael
Affiliation:
Health Service Executive
Citation:
Barry M.Medicines management programme: preferred medicines angiotensin-converting enzyme inhibitors. Dublin: Health Service Excutive; 2013. 12p.
Publisher:
Health Service Excutive (HSE)
Issue Date:
Sep-2013
URI:
http://hdl.handle.net/10147/325028
Additional Links:
http://www.hse.ie/yourmedicines
Item Type:
Report
Language:
en
Description:
There are ten licensed angiotensin‐converting enzyme (ACE) inhibitors available in Ireland.1 Annual expenditure on ACE inhibitors under the General Medical Services (GMS) scheme exceeds an estimated €15 million.2 The selection of a preferred ACE inhibitor under the Medicines Management Programme (MMP) is designed to support prescribers in choosing a medicine of proven safety and efficacy in the management of patients with cardiovascular conditions, particularly hypertension and heart failure. In selecting a preferred ACE inhibitor the MMP aims to enhance the quality of prescribing and provide value for money. The guidance may not be applicable to all patient populations, e.g. children and patients with congenital cardiac conditions, in which circumstances specialist advice should be sought. The use of ACE inhibitors is not recommended during the first trimester of pregnancy. ACE inhibitors are contraindicated during the second and third trimesters of pregnancy
Keywords:
MEDICINE; DRUG

Full metadata record

DC FieldValue Language
dc.contributor.authorBarry, Michaelen_GB
dc.date.accessioned2014-08-20T15:20:26Z-
dc.date.available2014-08-20T15:20:26Z-
dc.date.issued2013-09-
dc.identifier.citationBarry M.Medicines management programme: preferred medicines angiotensin-converting enzyme inhibitors. Dublin: Health Service Excutive; 2013. 12p.en_GB
dc.identifier.urihttp://hdl.handle.net/10147/325028-
dc.descriptionThere are ten licensed angiotensin‐converting enzyme (ACE) inhibitors available in Ireland.1 Annual expenditure on ACE inhibitors under the General Medical Services (GMS) scheme exceeds an estimated €15 million.2 The selection of a preferred ACE inhibitor under the Medicines Management Programme (MMP) is designed to support prescribers in choosing a medicine of proven safety and efficacy in the management of patients with cardiovascular conditions, particularly hypertension and heart failure. In selecting a preferred ACE inhibitor the MMP aims to enhance the quality of prescribing and provide value for money. The guidance may not be applicable to all patient populations, e.g. children and patients with congenital cardiac conditions, in which circumstances specialist advice should be sought. The use of ACE inhibitors is not recommended during the first trimester of pregnancy. ACE inhibitors are contraindicated during the second and third trimesters of pregnancyen_GB
dc.language.isoenen
dc.publisherHealth Service Excutive (HSE)en_GB
dc.relation.urlhttp://www.hse.ie/yourmedicinesen_GB
dc.subjectMEDICINEen_GB
dc.subjectDRUGen_GB
dc.titleMedicines management programme: preferred medicines angiotensin-converting enzyme inhibitorsen_GB
dc.typeReporten
dc.contributor.departmentHealth Service Executiveen_GB
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.